# Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

> **NCT01011205** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 893 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Advagraf
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Basiliximab
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT01011205
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-30
- **Primary completion:** 2013-01-04
- **Final completion:** 2013-01-04
- **Target enrollment:** 893 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011205, "Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01011205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*